Browse > Article
http://dx.doi.org/10.3345/kjp.2007.50.12.1180

Systemic lupus erythematosus  

Kim, Kwang-Nam (Department of Pediatrics, College of Medicine, Hallym University)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.12, 2007 , pp. 1180-1187 More about this Journal
Abstract
Systemic lupus erythematosus (SLE) is an episodic, multi-system, autoimmune disease characterized by widespread inflammation of blood vessels and connective tissues and by the presence of antinuclear antibodies (ANAs), especially antibodies to native (double-stranded) DNA (dsDNA). Its clinical manifestations are extremely variable, and its natural history is unpredictable. Untreated, SLE is often progressive and has a significant fatality rate. The most widely used criteria for the classification of SLE are those of the American College of Rheumatology (ACR), which were revised in 1982 and modified in 1997. The presence of four criteria have been diagnosed as a SLE. Rashes are common at onset and during active disease. The oral mucosa is the site of ulceration with SLE. Arthralgia and arthritis affect most children and these symptoms are short in duration and can be migratory. Lupus nephritis may be more frequent and of greater severity in children than in adults. The initial manifestation of nephritis is microscopic hematuria, followed by proteinuria. The most common neuropsychiatric symptoms are depression, psychosis(hallucination and paranoia) and headache. CNS disease is a major cause of morbidity and mortality. Pericarditis is the most common cardiac manifestation. Libman-Sacks endocarditis is less common in children. The most frequently described pleuropulmonary manifestations are pleural effusions, pleuritis, pneunonitis and pulmonary hemorrhage. During the active phase ESR, CRP, gamma globulin, ferritin and anti-dsDNA are elevated. Antibodies to dsDNA occur in children with active nephritis. Antibodies to the extractable nuclear antigens (Sm, Ro/SS-A, La/SS-B) are strongly associated with SLE. Specific treatment should be individualized and based on the severity of the disease. Sepsis has replaced renal failure as the most common cause of death.
Keywords
Systemic lupus erythematosus; SLE; ANA; dsDNA; ACR criteria; Lupus nephritis; CNSlupus; Sepsis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Klippel JH. Rheumatology. 3rd ed. London: Mosby Co, 2004:1292
2 Wananukul S, Watana D, Pongprasit P. Cutaneous manifestations of childhood systemic lupus erythematosus. Pediatr Dermatol 1998;15:342-6   DOI   ScienceOn
3 Smith FE, Sweet DE, Brunner CM, Davis JS. Avascular necrosis in SLE: an apparent predilection for young patients. Ann Rheum Dis 1976;35:227-32   DOI   ScienceOn
4 Silber TJ, Chatoor I, White PH. Psychiatric manifestations of systemic lupus erythematosus in children and adolescents. Clin Pediatr 1984;23:331-5   DOI   ScienceOn
5 Ansari A, Larson PH, Bates HD. Vascular manifestations of systemic lupus erythematosus. Angiology 1986;37:423-32   DOI   ScienceOn
6 Sharp GC, Irvin WS, Tan EM. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972;52:148-59   DOI   ScienceOn
7 Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-32   DOI
8 Mandell BF, Raps ED. Severe systemic hypersensitivity reaction of ibuprofen occurring after prolonged therapy. Am J Med 1987;82:817-20   DOI   ScienceOn
9 Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2002;10:140-7   DOI
10 Athreya BH, Rafferty JH, Sehgal GS, Lahita RG. Adenohypophyseal and sex hormones in pediatric rheumatic diseases. J Rheumatol 1993;20:725-30
11 Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56   DOI   ScienceOn
12 Lehman TJ, Edelheit BS, Onel KB. Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis. Ann Rheum Dis 2004;63:321-23   DOI   ScienceOn
13 Wallace DJ, Metzger AL, Stecher VJ. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6   DOI   ScienceOn
14 Ilowite NT, Samuel P, Ginzler E. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-63   DOI   ScienceOn
15 Fritzler MJ, Tan EM. Antibodies to histone in druginduced and idiopathic lupus erythematosus. J Clin Invest 1978;62:560-7   DOI
16 Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin A(Neoral) in the treatment of paediatric lupus nephritis with heavy protenuria. Br J Rheumatol 1998;37: 217-21   DOI
17 Cameron JS. Lupus nephritis in childhood and adolescene. Pediatr Nephrol 1994;8:230-49   DOI
18 Beaufils M, Kouki F, Mignon F. Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 1983;74:201-5   DOI   ScienceOn
19 Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med 1895;110:629-46   DOI
20 Clinic Rheumatology editors. Clinic Rheumatology IN: Systemic lupus erythematosus. 1st ed. Seoul: Korea Medicine Co, 2006:353-406
21 Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol 1989;16:1093-97.
22 Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematsus. Lupus 2001;10: 152-3   DOI   ScienceOn
23 Valesini G, Priori R, Francia A. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semi Immunopatho 1994;16:313-21
24 Libman E, Sacks B. A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924;33:701- 37   DOI
25 Malleson PN, Fung MY, Rosenberg AM. The incidence of pediatric rheumatic diseases: result from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 1996;23:1981-7
26 Kokk A, Horneff G, Wilgenbus KK. Acute lethal necrotising pancreatitis in childhood systemic lupus erythematosus. Possible toxicity of immunosuppressive therapy. Clin Exp Rheumatol 1995;13:399-403
27 Baehr G, Kemperer P, Schifrin A. A diffuse disease of the peripheral circulation usually associated with lupus erythematsus and endocraditis. Trans Assoc Am Phys 1935; 50:139
28 Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984;311:1528-33   DOI   ScienceOn
29 Miranda-Carus ME, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994;179:1317-30   DOI
30 Ginzler EM, Aranow C, Buyon J. A multicenter study of mycophenolate mofetil(MMF) vs intravenous cyclophosphamide( IVC) as induction therapy for severe lupus nephritis: preliminary results. Arthritis Rheum 2003;48:s647
31 Reichlin M. Antibodies to ribonuclear proteins in systemic lupus erythematosus. Rheum Dis Clin North Am 1994;20: 29-43
32 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725
33 Taylor PV, Scott JS, Gerlis LM. Maternal autoantibodies against fetal cardiac antigens in congenital complete heart block. N Engl J Med 1986;315:667-72   DOI   ScienceOn
34 Gibson T, Myers AR. Subclinical liver disease in systemic lupus erythemato년. J Rheumatol 1981;8:752-9
35 Smith CD, Cyr M. The history of lupus erythematosus from Hippocrates to Osler. Rheum Dis Clin North Am 1988;14:1-14
36 Au A, O'Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: association, visual outcomes, complications and treatment. Clin Exp Opthalmol 2004;32:87-100   DOI   ScienceOn
37 Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements: the Tart cell and the L.E. cell. Mayo Clin Proc 1948;23:25-8
38 Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 1996;39: 1050-5   DOI   ScienceOn
39 Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatments of systemic lupus erythematosus. Lupus 2001;10:154-61   DOI
40 Lafferty TE, Smith JB, Schuster SJ, DeHortius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Rrthritis Rheum 1997;40:775-8   DOI
41 Lehman TJ, Hanson V, Singsen BH. The role of antibodies directed against double-stranded DNA in the manifestations of systemic lupus erythematosus in childhood. J Pediatr 1980;96:657-61   DOI
42 Wang LC, Yang YH, Lu MY. Retrospective analysis of mortality and morbidity of pediatric SLE in the past two decades. J Mirobiol Immunol Infect 2003;36:203-8
43 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7   DOI   ScienceOn
44 Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England: relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8   DOI   ScienceOn
45 Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of Pediatrics Rheumatology. IN: Petty RE. Laxer RM, editors. Systemic Lupus Erythematosus. 5th ed. Philadelphia: Elsevier Saunders Ins, 2005:342-91
46 Incaprera M, Rindi L, Bazzichi A, Garzelli C. Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 1998;16:289-94
47 De Jongste JC, Neijens HJ, Duiverman EJ. Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child 1986;61:478-83   DOI